Invivyd, Inc.

https://www.invivyd.com/

Invivyd, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of monoclonal antibody (mAb) therapies aimed at protecting individuals from serious viral infectious diseases. The company's mission involves leveraging state-of-the-art viral surveillance and predictive modeling alongside advanced antibody engineering to build a robust pipeline of product candidates. Invivyd is headquartered in New Haven, CT.

Invivyd's key product is PEMGARDA (pemivibart), a half-life extended investigational monoclonal antibody that has received Emergency Use Authorization (EUA) from the U.S. FDA for the pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised individuals. The company is actively developing next-generation antibody candidates, including VYD2311, which is in Phase III clinical trials for COVID-19, and VBY329, a pre-clinical stage monoclonal antibody targeting RSV infections and measles. These efforts are supported by its proprietary INVYMAB platform, designed for the rapid and serial generation of new mAbs to adapt to evolving viral threats.

In recent news, Invivyd announced progress in its REVOLUTION Program, including the advancement of VMS063, a novel measles monoclonal antibody candidate, in April 2026. The company also launched the “Antibodies for Any Body” campaign in partnership with World Champion Skier Lindsey Vonn in April 2026. For the full year 2025, Invivyd reported net product revenue for PEMGARDA of $53.4 million. William Duke, M.B.A., serves as the Chief Financial Officer and Principal Executive Officer, with Michael Mina, M.D., Ph.D., as Chief Medical Officer. The company anticipates top-line data for VYD2311 in mid-2026, reinforcing its commitment to addressing unmet needs in infectious disease prevention and treatment.

Latest updates

Invivyd Chairman to Advocate for Monoclonal Antibody Role at POLITICO Health Care Summit

Event summary

  • Invivyd Chairman Marc Elia will speak at the POLITICO Health Care Summit on April 21, 2026, from 11:30 AM to 12:00 PM ET.
  • The summit, featuring speakers like Mehmet Oz and Mark Cuban, focuses on the future of American healthcare.
  • Elia's session will address the evolving role of monoclonal antibodies in viral disease prevention.
  • The event will be live-streamed between 9:00 AM and 1:00 PM ET.

The big picture

Invivyd's Chairman's participation in this high-profile summit signals a strategic effort to shape the narrative around preventative medicine and advocate for a greater role for monoclonal antibodies. This comes as the U.S. healthcare system re-evaluates its approach to infectious disease preparedness following recent public health crises, and as the company seeks to expand beyond its initial SARS-CoV-2 focus. The summit provides a platform to influence policy and potentially secure favorable regulatory conditions for future antibody development.

What we're watching

Policy Influence
How Elia's advocacy at the summit will influence the ongoing debate regarding federal stewardship versus private sector innovation in infectious disease prevention remains to be seen.
Market Adoption
Whether the broader acceptance of monoclonal antibodies as a preventative measure, beyond vaccines, can significantly expand Invivyd’s addressable market and revenue streams warrants close observation.
Competitive Response
The response from competitors like Cost Plus Drugs, who advocate for alternative pricing models, to Invivyd’s positioning on preventative monoclonal antibodies will likely shape the competitive dynamics of the market.

Invivyd Upsizes COVID-19 Trial, Advances Novel Measles Candidate

Event summary

  • Invivyd is expanding its DECLARATION Phase 3 COVID-19 trial by ~500 subjects, shifting the expected top-line results to Q3 2026.
  • The trial upsizing is based on accumulated data showing sufficient statistical power to support the high end of anticipated efficacy, with only 50% of the study completed.
  • Invivyd has initiated IND-enabling work for VMS063, a novel measles monoclonal antibody candidate, targeting IND readiness by late 2026.
  • The company is facing a resurgence of measles in the U.S., with infection rates exceeding 2025 levels and a significant immunity gap affecting millions.

The big picture

Invivyd's strategic pivot towards monoclonal antibody therapies for infectious diseases, particularly with the advancement of VMS063, represents a bet against the continued dominance of mRNA vaccines. The company’s focus on addressing unmet needs in measles treatment and prevention, coupled with the expanded COVID-19 trial, positions it to capitalize on a resurgence of infectious disease threats and potentially disrupt the current vaccine landscape. The measles market, while niche, represents a significant opportunity for a targeted therapeutic intervention.

What we're watching

Clinical Execution
The success of the expanded DECLARATION trial hinges on recruitment rates and continued event accumulation; delays could further push back results and impact investor confidence.
Regulatory Pathway
The FDA’s acceptance of Invivyd’s Pediatric Study Plan for VYD2311 will be a key indicator of the antibody’s overall regulatory trajectory and potential for pediatric market access.
Market Adoption
The commercial viability of VMS063 will depend on its ability to address the unmet need for measles treatment and prophylaxis, particularly among vulnerable populations hesitant to or unable to receive vaccination.

Invivyd Launches Consumer Education Campaign Amidst Viral Disease Concerns

Event summary

  • Invivyd launched the 'Antibodies for Any Body' national education campaign on April 7, 2026.
  • The campaign features a partnership with former ski champion Lindsey Vonn and a new online resource, AntibodiesforAnyBody.com.
  • The website includes an interactive wellness assessment designed to educate consumers about antibodies and immune health.
  • Invivyd's Chairman, Marc Elia, emphasized the campaign's goal of clarifying the relationship between lifestyle habits and immune function.

The big picture

Invivyd's campaign reflects a broader trend of biopharmaceutical companies directly engaging consumers with educational content, likely driven by heightened public awareness of infectious disease prevention. The partnership with a high-profile athlete like Lindsey Vonn signals an attempt to move beyond traditional medical channels and reach a wider audience. This strategy carries inherent risks related to brand association and potential regulatory challenges, but also represents a significant opportunity to build patient trust and potentially drive demand for Invivyd’s antibody therapies.

What we're watching

Consumer Adoption
The success of the campaign hinges on consumer engagement with the AntibodiesforAnyBody.com platform and the wellness assessment, which will dictate the return on investment.
Brand Perception
Lindsey Vonn's involvement carries significant brand equity; however, her recent recovery journey could either amplify or detract from the campaign's message depending on public perception.
Regulatory Scrutiny
Increased consumer focus on immune health may draw greater regulatory scrutiny of health-related marketing claims, potentially impacting Invivyd's future campaigns.

Invivyd Highlights Viral Adaptation Strategy at Vaccine Congress

Event summary

  • Invivyd’s Chief Scientific Officer, Robert Allen, presented at the World Vaccine Congress Washington on March 30, 2026.
  • The presentation focused on developing monoclonal antibody (mAb) therapies to address rapidly evolving viral threats.
  • Invivyd highlighted challenges in mAb utilization, including scalability, access, economics, and virus variation.
  • The company’s proprietary technology platform aims to develop mAb treatment and prevention options for vulnerable populations.
  • Invivyd received U.S. FDA emergency use authorization for a mAb in March 2024.

The big picture

Invivyd’s presentation underscores the ongoing need for adaptable therapeutic solutions in response to viral evolution, a challenge that traditional vaccination strategies struggle to fully address. The company’s focus on mAb therapies positions it within a growing market segment, but success hinges on overcoming significant hurdles related to cost, scalability, and the constant threat of viral mutation. The acknowledgement of limitations in current vaccinology suggests a shift towards a more layered approach to viral protection, where prophylactic measures are supplemented by therapeutic interventions.

What we're watching

Variant Pressure
The continued emergence of new viral variants will be a key determinant of Invivyd’s mAb efficacy and market relevance, potentially requiring frequent platform adaptation.
Scalability Hurdles
Invivyd’s ability to overcome scalability challenges will dictate its capacity to meet potential demand and compete effectively within the broader antibody market.
EUA Dependence
The duration and scope of the existing EUA for Invivyd’s mAb will significantly influence near-term revenue and the company’s ability to transition to broader commercialization.

Invivyd Advances COVID-19 Vaccine Alternative, Bolsters Cash Reserves

Event summary

  • Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2 million, a 25% year-over-year increase.
  • The company ended 2025 with $226.7 million in cash and cash equivalents following over $200 million in financing.
  • Phase 3 DECLARATION trial for VYD2311, a vaccine-alternative antibody, is fully enrolled and has received FDA Fast Track designation.
  • An IDMC review of DECLARATION trial data allowed enrollment of pregnant and breastfeeding women, and a potential trial resizing decision is expected in April.

The big picture

Invivyd is positioning itself as a key player in the evolving landscape of COVID-19 prevention, moving beyond traditional vaccination with an antibody-based alternative. The company’s significant cash reserves and ongoing clinical trials represent a substantial investment in this strategy, but success hinges on navigating regulatory hurdles and demonstrating a clear clinical and commercial advantage over existing vaccines. The IDMC’s decision to allow pregnant women in the trial is a positive signal, but the looming resizing decision introduces a significant uncertainty.

What we're watching

Clinical Trial Progress
The April resizing decision for the DECLARATION trial will be critical; a downsize could signal efficacy concerns or a need for a revised approach, while an upsize would indicate promising early results.
Regulatory Landscape
The FDA’s feedback on the LIBERTY trial, particularly regarding monitoring for myocarditis/pericarditis, suggests heightened scrutiny and could impact the approval pathway for VYD2311.
Commercial Execution
While PEMGARDA revenue growth is encouraging, Invivyd’s ability to translate VYD2311’s clinical success into substantial commercial adoption will be key to long-term value creation.

Invivyd Appoints Prominent Immunologist as CMO Amid Prophylactic Antibody Push

Event summary

  • Invivyd appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer, effective March 5, 2026.
  • Dr. Mina previously served as an assistant professor at Harvard T.H. Chan School of Public Health, Harvard Medical School, and Brigham and Women’s Hospital.
  • He has over 100 scientific publications and 10,000 citations, with expertise in antibodies, vaccines, and infectious diseases, particularly COVID-19.
  • Invivyd received FDA emergency use authorization in March 2024 for a monoclonal antibody.

The big picture

Invivyd’s appointment of a high-profile immunologist like Dr. Mina signals an intensified focus on prophylactic antibody therapies, a market segment poised for growth as viral threats evolve and public health priorities shift. The move underscores the increasing importance of scientific expertise in navigating complex regulatory landscapes and shaping public health policy, particularly in the wake of the COVID-19 pandemic. This hire is a bet that Invivyd can establish itself as a leader in a market currently facing questions about long-term efficacy and reimbursement.

What we're watching

Pipeline Expansion
The speed at which Dr. Mina can accelerate Invivyd’s pipeline expansion will be a key indicator of the strategic value of this hire, particularly given the company’s focus on prophylactic antibody therapies.
Regulatory Scrutiny
Increased regulatory scrutiny of monoclonal antibody therapies, especially in the context of viral evolution and variant emergence, could impact Invivyd’s ability to maintain EUA and approvals.
Market Adoption
The success of Invivyd’s strategy to provide Americans with choice in viral protection will depend on market adoption and willingness to pay for prophylactic antibody treatments, which remains an open question.

Invivyd Publication Validates Variant-Agnostic Antibody Protection Model

Event summary

  • Invivyd published a peer-reviewed analysis in *Infectious Diseases and Therapy* demonstrating a statistical model correlating antibody levels to clinical protection from COVID-19 variants.
  • The model, derived from data from the CANOPY Phase 3 clinical trial of pemivibart, aligns with prior Invivyd and external analyses.
  • The analysis suggests clinical efficacy can be predicted from stable epitope drugging, independent of SARS-CoV-2 variation.
  • PEMGARDA (pemivibart), an investigational monoclonal antibody, has received emergency use authorization from the FDA for pre-exposure prophylaxis.

The big picture

Invivyd’s findings challenge the conventional approach to COVID-19 antibody development, which often relies on extensive clinical trials for each variant. The ability to predict efficacy based on laboratory measurements could significantly streamline the development process and potentially broaden access to effective treatments. However, the model's reliance on stable epitopes highlights the ongoing risk of viral evolution rendering current antibodies ineffective.

What we're watching

Regulatory Impact
The potential for this correlate of protection model to accelerate regulatory pathways for Invivyd’s antibodies, reducing reliance on traditional animal models and lengthy trials, warrants close observation.
Variant Landscape
The continued emergence of SARS-CoV-2 variants with reduced susceptibility to pemivibart will test the model’s predictive power and potentially limit its utility, requiring ongoing monitoring of variant frequencies.
Market Adoption
The extent to which healthcare professionals and policymakers adopt this model for clinical decision-making and public health stewardship will determine the long-term commercial success of Invivyd’s antibody platform.

Invivyd Trial Design Signals Scrutiny of mRNA Vaccine Safety

Event summary

  • Invivyd is conducting a Phase 3 LIBERTY trial comparing its VYD2311 antibody to mRNA COVID vaccines, and evaluating co-administration.
  • The FDA has requested specific monitoring for adverse events (AESIs) like myocarditis/pericarditis in the LIBERTY trial due to risks associated with mRNA vaccines – a request not made in prior Invivyd trials.
  • The LIBERTY trial is designed to complement the ongoing DECLARATION trial, which is expected to release top-line data mid-2026.
  • VYD2311 leverages the same antibody backbone as pemivibart, an investigational mAb with existing Emergency Use Authorization.

The big picture

Invivyd's LIBERTY trial underscores a growing divergence in approaches to COVID-19 prevention, with a focus on antibody-mediated prophylaxis as a potential alternative to mRNA vaccines. The FDA's request for specific AESI monitoring highlights a heightened awareness of vaccine safety concerns, potentially driven by public perception and recent CDC surveys. This trial’s outcome could significantly influence the future of COVID-19 prevention strategies and the competitive landscape for Invivyd.

What we're watching

Regulatory Scrutiny
The FDA’s heightened scrutiny of AESIs in the LIBERTY trial suggests a potential shift in the regulatory landscape for antibody-based COVID prevention, which could impact future trial designs and approval pathways.
Clinical Adoption
Whether patient concerns about mRNA vaccine side effects, highlighted by the CDC survey, will meaningfully impact adoption of existing mRNA vaccines and create a sustained market opportunity for alternative prophylactic approaches like VYD2311 remains to be seen.
Trial Execution
The success of the LIBERTY trial hinges on timely enrollment and data collection, particularly given the FDA’s specific monitoring requests; any delays or complications could significantly impact Invivyd’s timeline for VYD2311 approval.

Invivyd Enlists Lindsey Vonn in Antibody Education Push

Event summary

  • Invivyd has partnered with former Olympic ski champion Lindsey Vonn for a national multimedia education campaign focused on antibodies and disease prevention.
  • The campaign is slated to launch in Spring 2026, following Vonn's return to competition and qualification for the Milan Cortina 2026 Olympic Winter Games.
  • Vonn will serve as the public-facing spokesperson, leveraging her personal brand and athletic background to connect antibody science with broader health and wellness conversations.
  • Invivyd received FDA emergency use authorization for a monoclonal antibody in March 2024.
  • Invivyd's revenue and market capitalization are not disclosed in the press release.

The big picture

Invivyd's partnership with a high-profile athlete represents a shift towards consumer-facing education in the biopharmaceutical sector, likely driven by a desire to build brand recognition and patient advocacy amidst ongoing public health concerns. This strategy contrasts with traditional, physician-focused marketing approaches and could be a template for other companies seeking to engage directly with consumers on complex medical topics. The effectiveness of this approach will depend heavily on Vonn’s ability to resonate with a broad audience and the campaign’s ability to cut through the noise of competing health information.

What we're watching

Campaign Efficacy
The success of the campaign hinges on Vonn's ability to translate complex scientific concepts into accessible messaging, and whether this translates to measurable shifts in public understanding and potentially, demand for Invivyd’s products.
Regulatory Landscape
The ongoing efficacy and authorization of Invivyd's monoclonal antibody, and the potential for future regulatory changes, will significantly impact the company's ability to capitalize on the increased public awareness generated by the campaign.
Viral Evolution
The continued evolution of SARS-CoV-2 and other infectious diseases will necessitate ongoing adaptation of antibody therapies and educational messaging, potentially requiring Invivyd to adjust its strategy and Vonn’s role.

Invivyd to Advance Long COVID Treatment Study Amid Regulatory Uncertainty

Event summary

  • Invivyd and the SPEAR Study Group plan to initiate a Phase 2 clinical trial in mid-2026 to evaluate VYD2311 for Long COVID and COVID vaccine injury.
  • The trial will assess safety, efficacy, and biological mechanisms using multiple antibody doses and placebo controls.
  • VYD2311 is an antibody with broad antiviral activity against SARS-CoV-2 variants, leveraging a backbone similar to Invivyd’s PEMGARDA.
  • The study aims to address the significant unmet need for effective Long COVID treatments, affecting millions of individuals.

The big picture

Invivyd's move to target Long COVID represents a strategic pivot beyond acute COVID-19 prevention, capitalizing on a large and underserved patient population. However, the lack of established treatment paradigms and the complex pathophysiology of Long COVID introduce significant development and regulatory risks. The partnership with the SPEAR Study Group underscores the need for specialized expertise in this emerging therapeutic area, but also highlights the potential for scientific disagreements and delays.

What we're watching

Regulatory Risk
The success of the trial hinges on continued FDA acceptance of novel therapeutic approaches for Long COVID, a condition with evolving diagnostic criteria and limited regulatory precedent.
Clinical Efficacy
Whether VYD2311 demonstrates meaningful clinical benefit in a placebo-controlled trial, given the heterogeneity of Long COVID presentations and the challenges in measuring functional improvement, remains a key uncertainty.
Variant Evolution
The ongoing evolution of SARS-CoV-2 variants could diminish VYD2311’s efficacy, requiring continuous monitoring and potential adaptation of the antibody to maintain its antiviral activity.

Invivyd Secures FDA Fast Track for COVID-19 Antibody

Event summary

  • Invivyd received Fast Track designation from the FDA for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention.
  • The designation aims to expedite development and review, potentially leading to priority review and rolling BLA submission.
  • DECLARATION, a Phase 3 clinical trial, is underway and expects top-line data mid-2026.
  • The trial will enroll 1770 participants and evaluate single and monthly doses of VYD2311 against placebo.

The big picture

The Fast Track designation underscores the ongoing need for COVID-19 prevention strategies, particularly for individuals with underlying risk factors, despite widespread vaccination efforts. Invivyd's approach, leveraging a proprietary antibody platform and building on previous assets like pemivibart and adintrevimab, represents a bet on a non-vaccine prophylactic solution in a market increasingly saturated with established vaccines and therapeutics. The trial results will be pivotal in determining whether this strategy can carve out a sustainable niche.

What we're watching

Clinical Efficacy
The success of DECLARATION will be critical; the trial's design, including both single and monthly dosing, introduces complexity and potential for varied outcomes that will heavily influence regulatory decisions.
Variant Evolution
The antibody's effectiveness against emerging COVID-19 variants remains a key risk, as Invivyd's platform relies on neutralizing contemporary lineages, and viral evolution could diminish efficacy.
Market Adoption
Given existing vaccine availability and potential for fatigue, the uptake of a vaccine-alternative antibody will depend on demonstrating a clear benefit for at-risk populations and ease of administration.

Invivyd Advances COVID-19 Antibody Candidate Through Phase 3 Trial

Event summary

  • Invivyd initiated the DECLARATION Phase 3 clinical trial for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention.
  • The trial will enroll 1,770 participants across three arms: single dose, monthly doses, and placebo.
  • Top-line data from the DECLARATION trial are expected mid-2026.
  • VYD2311 leverages the antibody backbone of Invivyd’s previously authorized mAbs, pemivibart and adintrevimab.

The big picture

Invivyd's DECLARATION trial represents a continued effort to provide vaccine alternatives for COVID-19 prevention, particularly targeting populations hesitant or unable to receive traditional vaccines. The trial's design, incorporating both single and monthly dosing regimens, suggests a strategic attempt to cater to diverse patient preferences and potentially secure broader market access. The success of VYD2311 will depend on demonstrating efficacy against evolving variants and navigating a competitive landscape of existing and emerging prophylactic solutions.

What we're watching

Efficacy
The trial's primary endpoint hinges on PCR-confirmed symptomatic COVID incidence reduction versus placebo; a failure to demonstrate significant efficacy could severely impact Invivyd's valuation and future development pipeline.
Variant Risk
Given the ongoing evolution of SARS-CoV-2, the trial's ability to demonstrate efficacy against emerging variants will be critical for long-term market viability, potentially requiring ongoing adaptation of VYD2311.
Commercialization
The success of the monthly dosing arm will be key to Invivyd's commercial strategy, as it could enable a recurring revenue model; however, adoption will depend on patient and payer acceptance of the cost and convenience.
CID: 176